CURE Pharmaceutical Takes First Step to Acquire Coeptis Pharmaceuticals and its Combination Drug for Osteoarthritis Pain and Hypertension

GlobeNewswire•November 14, 2019 OXNARD, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR) (“CURE”), an innovative drug delivery and development company, today announced that it purchased a $200,000 convertible promissory note issued by Coeptis Pharmaceuticals, Inc., a biopharmaceutical company engaged in the acquisition, development and commercialization of branded 505(b)(2) pharmaceutical products. This note represents…

Details

November 14, 2019

Wealth Minerals Provides Corporate Update

GlobeNewswireNovember 12, 2019 Closes Flow-Through Financing VANCOUVER, British Columbia, Nov. 12, 2019 (GLOBE NEWSWIRE) — Wealth Minerals Ltd. (the “Company” or “Wealth”) – (TSXV: WML; OTCQX: WMLLF; SSE: WMLCL; Frankfurt: EJZN), provides a corporate update the status of its assets and the Company’s corporate development, as well as announces the closing of its recently announced…

Details

November 12, 2019

Wealth Minerals Negotiates Land Access to Valsequillo Silver Project, Mexico

GlobeNewswire•October 30, 2019 VANCOUVER, British Columbia, Oct. 30, 2019 (GLOBE NEWSWIRE) — Wealth Minerals Ltd. (the “Company” or “Wealth”) – (TSXV: WML; OTCQX: WMLLF; SSE: WMLCL; Frankfurt: EJZN), reports it has successfully negotiated surface access rights to the Valsequillo Silver project (“Valsequillo” or the “Property”) located in southern Chihuahua state, Mexico (Figure 1). The Company…

Details

October 30, 2019

Wealth Minerals Signs Memorandum of Understanding with Uranium One Group

GlobeNewswire•October 15, 2019 VANCOUVER, British Columbia, Oct. 15, 2019 (GLOBE NEWSWIRE) — Wealth Minerals Ltd. (the “Company” or “Wealth”) – (TSXV: WML; OTCQX: WMLLF; SSE: WMLCL; Frankfurt: EJZN), is pleased to announce it has signed a strategic memorandum of understanding (the “MOU”) with Uranium One Group (“U1G”). The MOU provides for the acquisition (the “Proposed…

Details

October 15, 2019

CURE Pharmaceutical Debuts CUREform Drug Delivery Line Adding Chewables and Emulsions

GlobeNewswire•October 9, 2019 Alternative dosage demand drives company’s manufacturing expansion OXNARD, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, announces the expansion of its oral drug delivery product line creating CUREform™ which includes CUREfilm®, one of the most advanced oral thin films on the market today.…

Details

October 9, 2019

CURE Pharmaceutical Promotes Dr. Vered Gigi to Chief Scientific Officer

GlobeNewswire•October 1, 2019 Biopharma star brings extensive translational research experience as company advances its clinical indications OXNARD, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, has appointed Dr. Vered Gigi as its chief scientific officer. In this role, Dr. Gigi will oversee all CURE’s research and…

Details

October 1, 2019

CURE Pharmaceutical Takes First Step To Secure Hemp CBD Supply Chain by Partnering with Fytiko Farms

GlobeNewswire•August 21, 2019 OXNARD, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) –– CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has signed a deal with Oklahoma-based hemp grower Fytiko Farms. The deal gives CURE direct, guaranteed access to high-quality plant material for exclusive use in its proprietary oral thin film (OTF)…

Details

August 21, 2019

Wealth Receives Key Document from Chilean Environmental Agency Regarding Work at the Atacama Project

Wealth Receives Key Document from Chilean Environmental Agency Regarding Work at the Atacama Project GlobeNewswire•August 15, 2019 VANCOUVER, British Columbia, Aug. 15, 2019 (GLOBE NEWSWIRE) — Wealth Minerals Ltd. (the “Company” or “Wealth”) – (TSXV: WML; OTCQX: WMLLF; SSE: WMLCL; Frankfurt: EJZN), announces it has received from the Chilean Environmental Agency an initial work program…

Details

August 15, 2019